ISO 22679:2021-11 (E)

Cardiovascular implants - Transcatheter cardiac occluders

Contents

Page

Foreword v

Introduction vi

1 Scope 1

2 Normative references 1

3 Termsanddefinitions 2

4 Abbreviations 6

5 Fundamental requirements 7
5.1 General 7
5.2 Risk management 7

6 Device description 8
6.1 General 8
6.2 Intended use 8
6.3 Design inputs 8
6.3.1 Operational principles and specifications 8
6.3.2 Functional, performance and safety requirements 8
6.3.3 Implant procedure: Device and usability requirements 9
6.3.4 Packaging, labelling and sterilization 10
6.4 Design outputs 10
6.5 Design transfer (manufacturing verification or validation) 10

7 Designverificationandvalidation 10
7.1 General requirements 10
7.2 In vitro assessment 11
7.2.1 General 11
7.2.2 Test conditions, sample selection and reporting requirements 11
7.2.3 Material property assessment 12
7.2.4 Structural performance assessment 13
7.2.5 Component corrosion assessment 14
7.2.6 Visibility 14
7.2.7 Visual inspection 15
7.2.8 Dimensional verification 15
7.2.9 Device MRI compatibility 15
7.2.10 Simulated use assessment 15
7.2.11 Usability engineering process 15
7.2.12 Design- or procedure-specific testing 15
7.3 Preclinical in vivo evaluation 15
7.3.1 General 15
7.3.2 Overall requirements 15
7.3.3 Methods 17
7.3.4 Test report 18
7.4 Clinical investigations 19
7.4.1 General 19
7.4.2 Study considerations 20
7.4.3 Imaging assessment 21
7.4.4 Study design 21

7.4.5 Explant analysis 21
7.4.6 Pilot study considerations 22
7.4.7 Study endpoints 22
7.4.8 Ethical considerations 22
7.4.9 Pivotal studies: Distribution of subjects and investigators 23
7.4.10 Site qualification and training requirements 23
7.4.11 Study population 23
7.4.12 Statistical considerations 24
7.4.13 Sample size 25
7.4.14 Duration of study 25
7.4.15 Patient selection criteria 25
7.4.16 Clinical data requirements 26

Annex A (informative) Rationale for the provisions of this document 31

Annex B (informative) Transcatheter cardiac occluder hazard analysis example 34

Annex C (normative) Packaging 36

Annex D (normative) Product labels and instructions for use 37

Annex E (normative) Sterilization 38

Annex F (informative) Corrosion assessment 39

Annex G (informative) In vitro test guidelines for paediatric devices 42

Annex H (informative) Fatigue and durability assessment 44

Annex I (normative)Adverseeventclassificationduringclinicalinvestigation 50

Annex J (informative) Imaging protocol 55

Annex K (informative) Clinical investigation endpoints for transcatheter cardiac occluders: Suggestions for endpoints and their timing 56

Annex L (informative)Examplesofdesignspecifictesting 59

Annex M (informative) Guidelines for delivery system design evaluation 61

Annex N (normative) Preclinical in vivo evaluation 63

Annex O (informative) In vitro test pressure guidelines 66

Annex P (informative) Training for physicians and support staff 68

Bibliography 69